Insulet Corporation (PODD)
PODD's Q2 Earnings Top Estimates, FY'26 Sales View Cut, Stock Down
Insulet's Q2 results beat estimates on strong Omnipod demand and wider margins, but its 2026 revenue outlook takes a hit.
Insulet Corporation (PODD) Q2 2026 Earnings Call Transcript
Insulet Corporation (PODD) Q2 2026 Earnings Call Transcript
Insulet Q2 Earnings Call Highlights
Insulet NASDAQ: PODD reported second-quarter revenue growth of 23% on a constant-currency basis, supported by demand for its Omnipod insulin-delivery system in the U.S. and international markets, while raising its international outlook and reducing its U.S. and total-company revenue-growth expectations for 2026.
Insulet (PODD) Reports Q2 Earnings: What Key Metrics Have to Say
The headline numbers for Insulet (PODD) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Insulet (PODD) Beats Q2 Earnings and Revenue Estimates
Insulet (PODD) came out with quarterly earnings of $1.66 per share, beating the Zacks Consensus Estimate of $1.44 per share. This compares to earnings of $1.17 per share a year ago.
Here's Why Insulet (PODD) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Insulet Broadens Omnipod 5 Presence With Commercial Launch in Spain
PODD expands Omnipod 5 to Spain, marking its 20th country launch and adding Omnipod Discover to strengthen digital diabetes care.
Is it Prudent to Retain Insulet Stock in Your Portfolio for Now?
PODD's Omnipod 5 momentum and global growth support its outlook, but competitive pressure and macro costs may test its margin expansion plans.
Why Insulet (PODD) Could Beat Earnings Estimates Again
Insulet (PODD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Insulet Corporation: A High-Quality Growth Story Trading At A Reasonable PEG
Insulet is rated Buy due to strong growth, low TAM penetration, and a recurring revenue model supporting long-term upside. PODD's Omnipod system simplifies diabetes management with automation and integration, driving recurring pod sales and reducing patient burden. Despite GLP-1 concerns, PODD targets insulin-dependent patients, with only 40% U.S. Type 1 and 5% Type 2 pump penetration, leaving ample runway.
Do Options Traders Know Something About Insulet Stock We Don't?
Investors need to pay close attention to PODD stock based on the movements in the options market lately.
